Reducing overdiagnosis by polygenic risk-stratified screening: Findings from the Finnish section of the ERSPC

British Journal of Cancer

Volumn 113, Issue 7, 2015, Pages 1086-1093

  Pashayan, Nora ^a   Pharoah, Paul D P ^b   Schleutker, Johanna ^c   Talala, Kirsi ^d   Tammela, Teuvo L J ^e   Määttänen, Liisa ^d   Harrington, Patricia ^b   Tyrer, Jonathan ^b   Eeles, Rosalind ^f   Duffy, Stephen W ^g   Auvinen, Anssi ^h  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c UNIVERSITY OF TURKU   (Finland)

^d FINNISH CANCER REGISTRY   (Finland)

^e TAMPERE UNIVERSITY HOSPITAL   (Finland)

^f INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^g QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^h TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

ERSPC Finland; overdiagnosis; polygenic risk; prostate cancer; stratified screening

Indexed keywords

ADULT; AGED; ARTICLE; CALCULATION; CANCER SCREENING; CANCER STAGING; FINLAND; GENOTYPE; GLEASON SCORE; HIGH RISK POPULATION; HUMAN; MALE; MAXIMUM LIKELIHOOD METHOD; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; EARLY CANCER DIAGNOSIS; HEALTH SERVICE; MASS SCREENING; MIDDLE AGED; PREVENTION AND CONTROL; PROCEDURES; PROSTATIC NEOPLASMS; RISK ASSESSMENT; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA;

ADULT; AGED; EARLY DETECTION OF CANCER; FINLAND; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MASS SCREENING; MEDICAL OVERUSE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK ASSESSMENT;

EID: 84942991118     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.289     Document Type: Article

References (21)

1. Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y, Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D, Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO, Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J, Kolonel LN, Le ML, Hoover RN, Machiela MJ, Yeager M, Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M, Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T, Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J, Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M, Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF, Klarskov P, Roder MA, Iversen P, Thibodeau SN, McDonnell SK, Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM, Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE (2014) A meta-Analysis of 87, 040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46(10): 1103-1109
2. Day NE, Walter SD (1984) Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics 40(1): 1-14
3. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ (2003) Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95(12): 868-878
4. Draisma G, Etzioni R, Tsodikov A, Mariotto A, Wever E, Gulati R, Feuer E, de Koning H (2009) Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst 101(6): 374-383
5. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA, Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K, Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F, Henderson BE, Le ML, Lindstrom S, Kraft P, Hunter DJ, Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J, Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D, Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D (2013) Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 45(4): 385-391
6. Etzioni R, Penson DF, Legler JM, di TD, Boer R, Gann PH, Feuer EJ (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from US prostate cancer incidence trends. J Natl Cancer Inst 94(13): 981-990
7. Finne P, Stenman UH, Maattanen L, Makinen T, Tammela TL, Martikainen P, Ruutu M, Ala-Opas M, Aro J, Karhunen PJ, Lahtela J, Rissanen P, Juusela H, Hakama M, Auvinen A (2003) The Finnish trial of prostate cancer screening: where are we now? BJU Int 92(Suppl 2): 22-26
8. Hakama M, Auvinen A, Day NE, Miller AB (2007) Sensitivity in cancer screening. J Med Screen 14(4): 174-177
9. Loeb S (2012) Use of baseline prostate-specific antigen measurements to personalize prostate cancer screening. Eur Urol 61(5): 875-876
10. Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R (2014) Overdiagnosis and overtreatment of prostate cancer. Eur Urol 65(6): 1046-1055
11. Pashayan N, Duffy SW, Chowdhury S, Dent T, Burton H, Neal DE, Easton DF, Eeles R, Pharoah P (2011) Polygenic susceptibility to prostate and breast cancer: implications for personalised screening. Br J Cancer 104(10): 1656-1663
12. Pashayan N, Duffy SW, Neal DE, Hamdy FC, Donovan JL, Martin RM, Harrington P, Benlloch S, Amin Al OA, Shah M, Kote-Jarai Z, Easton DF, Eeles R, Pharoah PD (2015) Implications of polygenic risk-stratified screening for prostate cancer on overdiagnosis. Genet Medgim; e-pub ahead of print 8 January 2015; doi: 10.1038/gim.2014.192
13. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1): 33-36
14. Pharoah PD, Antoniou AC, Easton DF, Ponder BA (2008) Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 358(26): 2796-2803
15. Roobol MJ, Carlsson SV (2013) Risk stratification in prostate cancer screening. Nat Rev Urol 10(1): 38-48
16. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Maattanen L, Lilja H, Denis LJ, Recker F, Paez A, Bangma CH, Carlsson S, Puliti D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schaik RH, De Koning HJ, Moss SM, Auvinen A (2014) Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 384(9959): 2027-2035
17. Telesca D, Etzioni R, Gulati R (2008) Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics 64(1): 10-19
18. Teppo L, Pukkala E, Lehtonen M (1994) Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 33(4): 365-369
19. Walter SD, Day NE (1983) Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol 118(6): 865-886
20. Wang J, Lin M, Crenshaw A, Hutchinson A, Hicks B, Yeager M, Berndt S, Huang WY, Hayes RB, Chanock SJ, Jones RC, Ramakrishnan R (2009) High-Throughput single nucleotide polymorphism genotyping using nanofluidic Dynamic Arrays. BMC Genomics 10: 561
21. Wu GH, Auvinen A, Maattanen L, Tammela TL, Stenman UH, Hakama M, Yen AM, Chen HH (2012) Number of screens for overdetection as an indicator of absolute risk of overdiagnosis in prostate cancer screening. Int J Cancer 131(6): 1367-1375